Have you or your loved ones been diagnosed with pulmonary emphysema in alpha-1 pi deficiency?

You may be eligible to participate in a pulmonary emphysema in alpha-1 pi deficiency clinical trial.

Have you or your loved ones been diagnosed with pulmonary emphysema in alpha-1 pi deficiency? You may be eligible to participate in a pulmonary emphysema in alpha-1 pi deficiency clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Pulmonary Emphysema in Alpha-1 PI Deficiency Clinical Trial in Portland OR
NCT01983241 | Phase 3 | Interventional

Have you or your loved ones been diagnosed with pulmonary emphysema in alpha-1 pi deficiency?

You may be eligible to participate in a pulmonary emphysema in alpha-1 pi deficiency clinical trial.

Have you or your loved ones been diagnosed with pulmonary emphysema in alpha-1 pi deficiency? You may be eligible to participate in a pulmonary emphysema in alpha-1 pi deficiency clinical trial.

Recruiting

Male & Female

18 - 70

Years old

This study is looking to recruit 339 Participants

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.